QIA:XETRQIAGEN NV Analysis
Data as of 2026-03-14 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Qiagen N.V. is trading at €36.04, well above its DCF‑derived fair value of roughly €22, indicating the market is pricing in optimistic expectations despite modest 3.7% revenue growth and solid profitability (gross margin ~66%). Technicals are bearish: the 20‑day SMA (≈39.9) sits below both the 50‑day (≈41.8) and 200‑day (≈42.4) averages, the RSI is deep in oversold territory (~25), and the MACD histogram is negative, all pointing to downward pressure. However, volume is increasing and the stock remains above its identified support at €34.99, suggesting limited downside. The dividend yield is low (0.63%) but the payout ratio is modest (~13%), supporting dividend sustainability. Overall, the stock appears overvalued in the near term but benefits from a stable cash position, low leverage, and a resilient healthcare‑diagnostics franchise.
Market Outlook
Short Term
< 1 yearKey Factors
- Bearish technical signals (price below SMA, RSI ~25)
- Proximity to support level limiting downside
- Increasing volume suggesting potential short‑term stabilization
Medium Term
1–3 yearsKey Factors
- Analyst price targets median ~€46.9 imply ~30% upside
- Strong cash generation and low debt‑to‑equity
- Stable dividend with low payout ratio
Long Term
> 3 yearsKey Factors
- Steady profitability and high gross margin in a defensive sector
- Modest revenue growth limiting aggressive upside
- Overvaluation relative to DCF fair value
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.